Overview
NVS market data
Price History
NVS price chart · 1M
- O
- 150.57
- H
- 151.72
- L
- 150.25
- C
- 150.59
- Vol
- 137,357.00
Daily history from Jan 4, 2016
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $150.57
- Previous Close
- $150.33
- Day High
- $151.72
- Day Low
- $150.25
- 52 Week High
- $167.13
- 52 Week Low
- $119.25
- 7 Day Return
- +4.78%
- 30 Day Return
- +8.54%
- 90 Day Return
- +0.73%
- 1 Year Return
- +17.56%
- Daily Notional Volume
- $20.7M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 21.21 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $7.15 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.35 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 3.7% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 22.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $97.05 – $132.68 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $224.5B · P/B 5.45 · P/S 4.77.
Company News
10 captured
Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical OfficerGlobenewswire Inc ·
NVS Wins FDA Nod for Label Expansion of Immunology Drug RhapsidoZacks Investment Research ·
Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026Globenewswire Inc ·
Sironax Named to Fierce Biotech’s “Fierce 15” List of the Most Innovative and Promising Private Biotechs of 2026Globenewswire Inc ·
Europe Cancer Metabolism Based Therapeutics Market Forecast to 2035 by Modality, Route, Indication, and Therapy Sales | 25.3% CAGR Drives an $8.54 Billion OpportunityGlobenewswire Inc ·